drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00860 | DB11943 | 891 | 255 | [
"DDInter1513",
"DDInter495"
] | Prednisolone | Delafloxacin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Major | 2 | [
[
[
891,
25,
255
]
],
[
[
891,
63,
1648
],
[
1648,
23,
255
]
],
[
[
891,
23,
1283
],
[
1283,
24,
255
]
],
[
[
891,
63,
1512
],
[
1512,
... | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Ald... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide a... |
DB00960 | DB04843 | 887 | 1,511 | [
"DDInter1471",
"DDInter1149"
] | Pindolol | Mepenzolate | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
887,
24,
1511
]
],
[
[
887,
24,
1192
],
[
1192,
24,
1511
]
],
[
[
887,
63,
262
],
[
262,
24,
1511
]
],
[
[
887,
21,
28975
],
[
28975,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Cl... |
DB00413 | DB01176 | 1,346 | 537 | [
"DDInter1505",
"DDInter453"
] | Pramipexole | Cyclizine | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the mos... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1346,
24,
537
]
],
[
[
1346,
63,
1242
],
[
1242,
24,
537
]
],
[
[
1346,
24,
104
],
[
104,
1,
537
]
],
[
[
1346,
24,
13
],
[
13,
... | [
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Met... |
DB06717 | DB08899 | 875 | 129 | [
"DDInter778",
"DDInter649"
] | Fosaprepitant | Enzalutamide | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
875,
24,
129
]
],
[
[
875,
63,
918
],
[
918,
1,
129
]
],
[
[
875,
21,
28703
],
[
28703,
60,
129
]
],
[
[
875,
63,
608
],
[
608,
... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Fosaprepitant (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Fosaprepitant may cause a modera... |
DB04844 | DB08899 | 843 | 129 | [
"DDInter1778",
"DDInter649"
] | Tetrabenazine | Enzalutamide | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
843,
24,
129
]
],
[
[
843,
63,
918
],
[
918,
1,
129
]
],
[
[
843,
6,
12523
],
[
12523,
45,
129
]
],
[
[
843,
21,
28921
],
[
28921,
... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]... | Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Tetrabenazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Tetrabenazine (Compound) causes Dizziness (Side Effe... |
DB01309 | DB09038 | 1,254 | 1,450 | [
"DDInter933",
"DDInter636"
] | Insulin glulisine | Empagliflozin | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1254,
24,
1450
]
],
[
[
1254,
62,
1103
],
[
1103,
23,
1450
]
],
[
[
1254,
63,
461
],
[
461,
24,
1450
]
],
[
[
1254,
24,
659
],
[
659,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
... | Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Timolol ... |
DB00443 | DB06717 | 251 | 875 | [
"DDInter195",
"DDInter778"
] | Betamethasone | Fosaprepitant | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
251,
24,
875
]
],
[
[
251,
24,
723
],
[
723,
1,
875
]
],
[
[
251,
21,
28757
],
[
28757,
60,
875
]
],
[
[
251,
63,
1101
],
[
1101,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Betamethasone (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Fosaprepitant (Compound)
Betamethasone may cause a modera... |
DB08881 | DB09101 | 868 | 70 | [
"DDInter1925",
"DDInter633"
] | Vemurafenib | Elvitegravir | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome ... | Moderate | 1 | [
[
[
868,
24,
70
]
],
[
[
868,
24,
1017
],
[
1017,
63,
70
]
],
[
[
868,
25,
982
],
[
982,
63,
70
]
],
[
[
868,
24,
1040
],
[
1040,
24... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elvitegravir"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Elvitegravir
Vemurafenib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may ca... |
DB00092 | DB09322 | 58 | 1,114 | [
"DDInter40",
"DDInter1966"
] | Alefacept | Zinc sulfate | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
58,
23,
1114
]
],
[
[
58,
24,
66
],
[
66,
23,
1114
]
],
[
[
58,
24,
1093
],
[
1093,
62,
1114
]
],
[
[
58,
63,
1057
],
[
1057,
23... | [
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizum... |
DB00394 | DB01001 | 218 | 688 | [
"DDInter168",
"DDInter1632"
] | Beclomethasone dipropionate | Salbutamol | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Bec... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Minor | 0 | [
[
[
218,
23,
688
]
],
[
[
218,
23,
455
],
[
455,
24,
688
]
],
[
[
218,
23,
1148
],
[
1148,
63,
688
]
],
[
[
218,
5,
11649
],
[
11649,
... | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
... | Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when ta... |
DB00281 | DB11979 | 608 | 1,320 | [
"DDInter1066",
"DDInter625"
] | Lidocaine | Elagolix | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Minor | 0 | [
[
[
608,
23,
1320
]
],
[
[
608,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
608,
23,
1249
],
[
1249,
24,
1320
]
],
[
[
608,
24,
1375
],
[
1375,
... | [
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Nafcillin and Nafcillin... |
DB01097 | DB01230 | 1,377 | 795 | [
"DDInter1033",
"DDInter1416"
] | Leflunomide | Pemoline | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Major | 2 | [
[
[
1377,
25,
795
]
],
[
[
1377,
25,
1613
],
[
1613,
63,
795
]
],
[
[
1377,
64,
305
],
[
305,
24,
795
]
],
[
[
1377,
25,
1510
],
[
1510,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pemoline"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon ... | Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Leflunomide may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli... |
DB00519 | DB01240 | 1,638 | 885 | [
"DDInter1843",
"DDInter657"
] | Trandolapril | Epoprostenol | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1638,
24,
885
]
],
[
[
1638,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1638,
21,
28936
],
[
28936,
60,
885
]
],
[
[
1638,
24,
1512
],
[
1512... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Trandolapril (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Trandolapril may cause a... |
DB12015 | DB14568 | 1,033 | 982 | [
"DDInter53",
"DDInter1000"
] | Alpelisib | Ivosidenib | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolis... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1033,
24,
982
]
],
[
[
1033,
63,
168
],
[
168,
23,
982
]
],
[
[
1033,
63,
700
],
[
700,
24,
982
]
],
[
[
1033,
62,
1135
],
[
1135,
... | [
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvast... |
DB01278 | DB01324 | 1,021 | 178 | [
"DDInter1506",
"DDInter1490"
] | Pramlintide | Polythiazide | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1021,
24,
178
]
],
[
[
1021,
63,
674
],
[
674,
40,
178
]
],
[
[
1021,
63,
85
],
[
85,
23,
178
]
],
[
[
1021,
24,
1511
],
[
1511,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a minor interacti... |
DB00918 | DB01105 | 1,373 | 222 | [
"DDInter49",
"DDInter1665"
] | Almotriptan | Sibutramine | Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
1373,
25,
222
]
],
[
[
1373,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1373,
21,
29356
],
[
29356,
60,
222
]
],
[
[
1373,
24,
384
],
[
384,
... | [
[
[
"Almotriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Almotriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibu... | Almotriptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Almotriptan (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Almotriptan may cause a moderate interaction that could exacerbate diseases wh... |
DB00208 | DB08896 | 1,018 | 292 | [
"DDInter1804",
"DDInter1576"
] | Ticlopidine | Regorafenib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1018,
25,
292
]
],
[
[
1018,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1018,
21,
29276
],
[
29276,
60,
292
]
],
[
[
1018,
24,
643
],
[
643,
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Rego... | Ticlopidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Ticlopidine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Regorafenib (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafa... |
DB00794 | DB00902 | 759 | 104 | [
"DDInter1521",
"DDInter1168"
] | Primidone | Methdilazine | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
759,
24,
104
]
],
[
[
759,
63,
13
],
[
13,
24,
104
]
],
[
[
759,
24,
820
],
[
820,
1,
104
]
],
[
[
759,
24,
537
],
[
537,
40,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine a... |
DB00095 | DB10795 | 66 | 221 | [
"DDInter623",
"DDInter1486"
] | Efalizumab | Poliovirus type 1 antigen (formaldehyde inactivated) | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
66,
24,
221
]
],
[
[
66,
24,
36
],
[
36,
24,
221
]
],
[
[
66,
63,
581
],
[
581,
24,
221
]
],
[
[
66,
25,
1510
],
[
1510,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wit... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Efalizumab may cause a moderate interaction that could exacerbate diseases... |
DB00006 | DB11703 | 942 | 405 | [
"DDInter217",
"DDInter9"
] | Bivalirudin | Acalabrutinib | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
942,
25,
405
]
],
[
[
942,
24,
383
],
[
383,
24,
405
]
],
[
[
942,
24,
738
],
[
738,
63,
405
]
],
[
[
942,
24,
804
],
[
804,
25,... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00357 | DB01072 | 1,051 | 915 | [
"DDInter71",
"DDInter129"
] | Aminoglutethimide | Atazanavir | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Moderate | 1 | [
[
[
1051,
24,
915
]
],
[
[
1051,
24,
1327
],
[
1327,
1,
915
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
915
]
],
[
[
1051,
21,
28921
],
[
28921,... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atazanavir (Compound)
Aminoglutethimide (Compound) causes Dizziness (Side ... |
DB01285 | DB01359 | 708 | 729 | [
"DDInter445",
"DDInter1417"
] | Corticotropin | Penbutolol | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
708,
24,
729
]
],
[
[
708,
63,
461
],
[
461,
1,
729
]
],
[
[
708,
63,
699
],
[
699,
40,
729
]
],
[
[
708,
63,
126
],
[
126,
23,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Cortic... |
DB00640 | DB08899 | 1,585 | 129 | [
"DDInter31",
"DDInter649"
] | Adenosine | Enzalutamide | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1585,
24,
129
]
],
[
[
1585,
24,
918
],
[
918,
1,
129
]
],
[
[
1585,
21,
28921
],
[
28921,
60,
129
]
],
[
[
1585,
63,
79
],
[
79,
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Adenosine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Adenosine may cause a moderate interac... |
DB05679 | DB09312 | 1,683 | 967 | [
"DDInter1907",
"DDInter103"
] | Ustekinumab | Antilymphocyte immunoglobulin (horse) | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Moderate | 1 | [
[
[
1683,
24,
967
]
],
[
[
1683,
23,
1193
],
[
1193,
62,
967
]
],
[
[
1683,
62,
1461
],
[
1461,
62,
967
]
],
[
[
1683,
24,
1531
],
[
1531,... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"... | Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse)
Ustekinumab may cause a minor interaction that can limit clinical effects when t... |
DB06207 | DB08901 | 910 | 1,468 | [
"DDInter1667",
"DDInter1492"
] | Silodosin | Ponatinib | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
910,
24,
1468
]
],
[
[
910,
63,
478
],
[
478,
24,
1468
]
],
[
[
910,
6,
4973
],
[
4973,
45,
1468
]
],
[
[
910,
21,
28883
],
[
28883,
... | [
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Silodosin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Silodosin (Compound) cause... |
DB00218 | DB08907 | 1,176 | 1,344 | [
"DDInter1247",
"DDInter280"
] | Moxifloxacin | Canagliflozin | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1176,
24,
1344
]
],
[
[
1176,
24,
549
],
[
549,
1,
1344
]
],
[
[
1176,
21,
28873
],
[
28873,
60,
1344
]
],
[
[
1176,
1,
739
],
[
739,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Moxifloxacin (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Canagliflozin (Compound)
Moxifloxacin (Compound... |
DB00418 | DB00902 | 536 | 104 | [
"DDInter1650",
"DDInter1168"
] | Secobarbital | Methdilazine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
536,
24,
104
]
],
[
[
536,
24,
13
],
[
13,
24,
104
]
],
[
[
536,
24,
820
],
[
820,
1,
104
]
],
[
[
536,
24,
537
],
[
537,
40,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Alimema... |
DB00991 | DB01105 | 97 | 222 | [
"DDInter1358",
"DDInter1665"
] | Oxaprozin | Sibutramine | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
97,
24,
222
]
],
[
[
97,
21,
29215
],
[
29215,
60,
222
]
],
[
[
97,
24,
384
],
[
384,
62,
222
]
],
[
[
97,
62,
752
],
[
752,
23,... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Ecchymosis"
],
[
"Ecchymosis",
"{u} (Side Effect) is cau... | Oxaprozin (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutram... |
DB00365 | DB00738 | 839 | 485 | [
"DDInter842",
"DDInter1420"
] | Grepafloxacin | Pentamidine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Major | 2 | [
[
[
839,
25,
485
]
],
[
[
839,
23,
112
],
[
112,
62,
485
]
],
[
[
839,
25,
971
],
[
971,
63,
485
]
],
[
[
839,
24,
1450
],
[
1450,
6... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Me... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pentamidine
Grepafloxacin may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritin... |
DB00366 | DB00434 | 1,594 | 13 | [
"DDInter600",
"DDInter459"
] | Doxylamine | Cyproheptadine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
1594,
24,
13
]
],
[
[
1594,
24,
104
],
[
104,
63,
13
]
],
[
[
1594,
63,
1302
],
[
1302,
24,
13
]
],
[
[
1594,
6,
10104
],
[
10104,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline... |
DB00495 | DB05015 | 139 | 1,077 | [
"DDInter1961",
"DDInter174"
] | Zidovudine | Belinostat | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
139,
24,
1077
]
],
[
[
139,
63,
482
],
[
482,
24,
1077
]
],
[
[
139,
24,
869
],
[
869,
24,
1077
]
],
[
[
139,
24,
1430
],
[
1430,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotec... |
DB00881 | DB11827 | 954 | 433 | [
"DDInter1554",
"DDInter669"
] | Quinapril | Ertugliflozin | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
954,
24,
433
]
],
[
[
954,
24,
959
],
[
959,
24,
433
]
],
[
[
954,
63,
251
],
[
251,
24,
433
]
],
[
[
954,
40,
1058
],
[
1058,
2... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Beta... |
DB01045 | DB06697 | 463 | 436 | [
"DDInter1590",
"DDInter121"
] | Rifampicin | Artemether | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Major | 2 | [
[
[
463,
25,
436
]
],
[
[
463,
6,
6017
],
[
6017,
45,
436
]
],
[
[
463,
25,
283
],
[
283,
63,
436
]
],
[
[
463,
24,
1220
],
[
1220,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Artemet... | Rifampicin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Artemether (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Rifampicin may cause a moderate i... |
DB00603 | DB06292 | 303 | 549 | [
"DDInter1137",
"DDInter474"
] | Medroxyprogesterone acetate | Dapagliflozin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
303,
24,
549
]
],
[
[
303,
24,
1344
],
[
1344,
40,
549
]
],
[
[
303,
6,
8374
],
[
8374,
45,
549
]
],
[
[
303,
21,
29222
],
[
29222,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Medroxyprogesterone ... |
DB00191 | DB01278 | 73 | 1,021 | [
"DDInter1447",
"DDInter1506"
] | Phentermine | Pramlintide | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
73,
24,
1021
]
],
[
[
73,
24,
9
],
[
9,
63,
1021
]
],
[
[
73,
25,
1466
],
[
1466,
24,
1021
]
],
[
[
73,
35,
22
],
[
22,
63,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine... |
DB00563 | DB08880 | 663 | 1,510 | [
"DDInter1174",
"DDInter1771"
] | Methotrexate | Teriflunomide | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
663,
25,
1510
]
],
[
[
663,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
663,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
663,
24,
1136
],
[
1136,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vita... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpe... |
DB00379 | DB14724 | 143 | 48 | [
"DDInter1206",
"DDInter634"
] | Mexiletine | Emapalumab | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
143,
24,
48
]
],
[
[
143,
64,
1031
],
[
1031,
24,
48
]
],
[
[
143,
63,
608
],
[
608,
24,
48
]
],
[
[
143,
64,
1031
],
[
1031,
24... | [
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Mexiletine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Theophylline"
],
[
"Theophyl... | Mexiletine may lead to a major life threatening interaction when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may caus... |
DB00604 | DB12245 | 1,425 | 823 | [
"DDInter385",
"DDInter1863"
] | Cisapride | Triclabendazole | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1425,
25,
823
]
],
[
[
1425,
23,
1247
],
[
1247,
23,
823
]
],
[
[
1425,
25,
1612
],
[
1612,
24,
823
]
],
[
[
1425,
64,
1010
],
[
1010,... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sul... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Cisapride may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsav... |
DB00005 | DB00041 | 1,057 | 1,648 | [
"DDInter687",
"DDInter38"
] | Etanercept | Aldesleukin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Major | 2 | [
[
[
1057,
25,
1648
]
],
[
[
1057,
25,
322
],
[
322,
63,
1648
]
],
[
[
1057,
24,
1367
],
[
1367,
63,
1648
]
],
[
[
1057,
25,
1184
],
[
1184... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} ... | Etanercept may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) a... |
DB00388 | DB06704 | 1,636 | 247 | [
"DDInter1453",
"DDInter952"
] | Phenylephrine | Iobenguane (I-131) | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
1636,
37,
247
]
],
[
[
1636,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1636,
63,
461
],
[
461,
25,
247
]
],
[
[
1636,
25,
1161
],
[
1161,... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Phenylephrine may lead to a major life threatening interaction when taken with Iobenguane
Phenylephrine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
... |
DB00030 | DB01132 | 1,685 | 1,130 | [
"DDInter934",
"DDInter1472"
] | Insulin human | Pioglitazone | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1685,
24,
1130
]
],
[
[
1685,
23,
333
],
[
333,
23,
1130
]
],
[
[
1685,
24,
566
],
[
566,
23,
1130
]
],
[
[
1685,
24,
1072
],
[
1072,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Insulin human",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],
... | Insulin human may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel ... |
DB04911 | DB14723 | 968 | 159 | [
"DDInter1347",
"DDInter1026"
] | Oritavancin | Larotrectinib | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
968,
24,
159
]
],
[
[
968,
24,
466
],
[
466,
23,
159
]
],
[
[
968,
63,
11
],
[
11,
24,
159
]
],
[
[
968,
24,
1593
],
[
1593,
24,... | [
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and... |
DB05294 | DB08865 | 1,069 | 1,593 | [
"DDInter1917",
"DDInter448"
] | Vandetanib | Crizotinib | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1069,
25,
1593
]
],
[
[
1069,
6,
5304
],
[
5304,
45,
1593
]
],
[
[
1069,
6,
3051
],
[
3051,
46,
1593
]
],
[
[
1069,
21,
28771
],
[
287... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vandetanib",
"{u} (Compound) binds {v} (Gene)",
"ABL2"
],
[
"ABL2",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"... | Vandetanib (Compound) binds ABL2 (Gene) and ABL2 (Gene) is bound by Crizotinib (Compound)
Vandetanib (Compound) binds ERBB3 (Gene) and ERBB3 (Gene) is upregulated by Crizotinib (Compound)
Vandetanib (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compou... |
DB01238 | DB13928 | 673 | 1,385 | [
"DDInter118",
"DDInter1660"
] | Aripiprazole | Semaglutide | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
673,
24,
1385
]
],
[
[
673,
24,
1154
],
[
1154,
24,
1385
]
],
[
[
673,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
673,
40,
1630
],
[
1630,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide an... |
DB04865 | DB15091 | 4 | 676 | [
"DDInter1335",
"DDInter1901"
] | Omacetaxine mepesuccinate | Upadacitinib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
4,
25,
676
]
],
[
[
4,
24,
1430
],
[
1430,
24,
676
]
],
[
[
4,
25,
283
],
[
283,
24,
676
]
],
[
[
4,
63,
248
],
[
248,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with ... |
DB00312 | DB01619 | 1,023 | 830 | [
"DDInter1423",
"DDInter1441"
] | Pentobarbital | Phenindamine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1023,
24,
830
]
],
[
[
1023,
24,
537
],
[
537,
40,
830
]
],
[
[
1023,
24,
13
],
[
13,
24,
830
]
],
[
[
1023,
24,
104
],
[
104,
1... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interact... |
DB08870 | DB11732 | 850 | 1,097 | [
"DDInter228",
"DDInter1027"
] | Brentuximab vedotin | Lasmiditan | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
850,
24,
1097
]
],
[
[
850,
24,
971
],
[
971,
63,
1097
]
],
[
[
850,
63,
478
],
[
478,
24,
1097
]
],
[
[
850,
24,
384
],
[
384,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteriti... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00682 | DB00860 | 126 | 891 | [
"DDInter1951",
"DDInter1513"
] | Warfarin | Prednisolone | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
126,
24,
891
]
],
[
[
126,
63,
175
],
[
175,
40,
891
]
],
[
[
126,
64,
1561
],
[
1561,
24,
891
]
],
[
[
126,
24,
167
],
[
167,
1... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Warfarin may lead to a major life threatening interaction when taken with Testosterone and Testosterone may cause a moderate interaction that could exacer... |
DB00748 | DB00802 | 662 | 1,322 | [
"DDInter297",
"DDInter43"
] | Carbinoxamine | Alfentanil | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Moderate | 1 | [
[
[
662,
24,
1322
]
],
[
[
662,
24,
411
],
[
411,
1,
1322
]
],
[
[
662,
63,
1454
],
[
1454,
1,
1322
]
],
[
[
662,
6,
8374
],
[
8374,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Alfentanil (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil and Sufentanil (Compound) resembles Alfentanil (... |
DB00865 | DB06203 | 939 | 1,002 | [
"DDInter187",
"DDInter51"
] | Benzphetamine | Alogliptin | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
939,
24,
1002
]
],
[
[
939,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
939,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
939,
21,
29232
],
[
29232,... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Benzphetamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Benzphetamine (Compound) causes Urticaria (Side Effect) an... |
DB00431 | DB06077 | 1,503 | 879 | [
"DDInter1072",
"DDInter1102"
] | Lindane | Lumateperone | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
1503,
24,
879
]
],
[
[
1503,
24,
407
],
[
407,
63,
879
]
],
[
[
1503,
63,
999
],
[
999,
24,
879
]
],
[
[
1503,
24,
104
],
[
104,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opiu... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazi... |
DB00087 | DB09074 | 599 | 1,362 | [
"DDInter41",
"DDInter1327"
] | Alemtuzumab | Olaparib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
599,
24,
1362
]
],
[
[
599,
24,
725
],
[
725,
63,
1362
]
],
[
[
599,
24,
896
],
[
896,
24,
1362
]
],
[
[
599,
63,
491
],
[
491,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Eto... |
DB01021 | DB09472 | 674 | 1,383 | [
"DDInter1861",
"DDInter1693"
] | Trichlormethiazide | Sodium sulfate | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
674,
24,
1383
]
],
[
[
674,
24,
1264
],
[
1264,
24,
1383
]
],
[
[
674,
1,
1014
],
[
1014,
24,
1383
]
],
[
[
674,
40,
1326
],
[
1326,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Trichlormethiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate inte... |
DB01244 | DB11837 | 762 | 1,297 | [
"DDInter192",
"DDInter1351"
] | Bepridil | Osilodrostat | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
762,
25,
1297
]
],
[
[
762,
23,
1135
],
[
1135,
23,
1297
]
],
[
[
762,
62,
112
],
[
112,
23,
1297
]
],
[
[
762,
24,
578
],
[
578,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole... |
DB00332 | DB00420 | 1,089 | 508 | [
"DDInter970",
"DDInter1532"
] | Ipratropium | Promazine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Moderate | 1 | [
[
[
1089,
24,
508
]
],
[
[
1089,
24,
146
],
[
146,
40,
508
]
],
[
[
1089,
24,
1264
],
[
1264,
63,
508
]
],
[
[
1089,
24,
1630
],
[
1630,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
[... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Promazine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could ... |
DB00912 | DB09054 | 473 | 384 | [
"DDInter1581",
"DDInter905"
] | Repaglinide | Idelalisib | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
473,
24,
384
]
],
[
[
473,
24,
222
],
[
222,
23,
384
]
],
[
[
473,
63,
1230
],
[
1230,
23,
384
]
],
[
[
473,
24,
72
],
[
72,
24,... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Cita... |
DB00675 | DB01100 | 888 | 1,568 | [
"DDInter1744",
"DDInter1470"
] | Tamoxifen | Pimozide | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
888,
25,
1568
]
],
[
[
888,
64,
78
],
[
78,
40,
1568
]
],
[
[
888,
63,
1557
],
[
1557,
25,
1568
]
],
[
[
888,
6,
6365
],
[
6365,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} (Comp... | Tamoxifen may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interaction when taken wi... |
DB01165 | DB06663 | 1,539 | 1,154 | [
"DDInter1325",
"DDInter1398"
] | Ofloxacin | Pasireotide | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1539,
25,
1154
]
],
[
[
1539,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1539,
62,
112
],
[
112,
23,
1154
]
],
[
[
1539,
24,
1385
],
[
13... | [
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Ofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by ... | Ofloxacin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken w... |
DB01142 | DB01208 | 1,264 | 945 | [
"DDInter593",
"DDInter1705"
] | Doxepin | Sparfloxacin | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
1264,
25,
945
]
],
[
[
1264,
63,
739
],
[
739,
1,
945
]
],
[
[
1264,
64,
1176
],
[
1176,
1,
945
]
],
[
[
1264,
24,
1539
],
[
1539,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Doxepin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Doxepin m... |
DB00295 | DB11732 | 475 | 1,097 | [
"DDInter1244",
"DDInter1027"
] | Morphine | Lasmiditan | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
475,
24,
1097
]
],
[
[
475,
24,
971
],
[
971,
63,
1097
]
],
[
[
475,
63,
701
],
[
701,
24,
1097
]
],
[
[
475,
24,
1614
],
[
1614,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemas... |
DB00620 | DB04868 | 175 | 478 | [
"DDInter1855",
"DDInter1293"
] | Triamcinolone | Nilotinib | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
175,
24,
478
]
],
[
[
175,
5,
11555
],
[
11555,
44,
478
]
],
[
[
175,
6,
8374
],
[
8374,
45,
478
]
],
[
[
175,
7,
16662
],
[
16662,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Triamcinolone",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (D... | Triamcinolone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Triamcinolone (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Nilotinib ... |
DB00493 | DB00682 | 1,087 | 126 | [
"DDInter323",
"DDInter1951"
] | Cefotaxime | Warfarin | Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under var... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1087,
24,
126
]
],
[
[
1087,
63,
597
],
[
597,
24,
126
]
],
[
[
1087,
40,
731
],
[
731,
63,
126
]
],
[
[
1087,
24,
361
],
[
361,
... | [
[
[
"Cefotaxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Cefotaxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[... | Cefotaxime may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Cefotaxime (Compound) resembles Ceftizoxime (Compound) and Ceftizoxime may cause a moderate interaction ... |
DB09038 | DB09564 | 1,450 | 1,296 | [
"DDInter636",
"DDInter930"
] | Empagliflozin | Insulin degludec | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1450,
24,
1296
]
],
[
[
1450,
63,
274
],
[
274,
23,
1296
]
],
[
[
1450,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
1450,
63,
17
],
[
17,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Empagliflozin may cause a minor interaction that can limit clinical effects when taken with Amcinonid... |
DB00501 | DB04868 | 752 | 478 | [
"DDInter380",
"DDInter1293"
] | Cimetidine | Nilotinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
752,
24,
478
]
],
[
[
752,
23,
1468
],
[
1468,
63,
478
]
],
[
[
752,
6,
6017
],
[
6017,
45,
478
]
],
[
[
752,
21,
28963
],
[
28963,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Cimetidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Cimetidine (Compound) ca... |
DB04844 | DB08875 | 843 | 1,618 | [
"DDInter1778",
"DDInter262"
] | Tetrabenazine | Cabozantinib | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
843,
25,
1618
]
],
[
[
843,
62,
112
],
[
112,
23,
1618
]
],
[
[
843,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
843,
63,
480
],
[
480,
... | [
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Tetrabenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"M... | Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuri... |
DB00938 | DB01364 | 455 | 22 | [
"DDInter1635",
"DDInter650"
] | Salmeterol | Ephedrine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
455,
24,
22
]
],
[
[
455,
63,
80
],
[
80,
24,
22
]
],
[
[
455,
24,
1529
],
[
1529,
63,
22
]
],
[
[
455,
24,
280
],
[
280,
1,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Me... |
DB01064 | DB01224 | 1,148 | 623 | [
"DDInter987",
"DDInter1553"
] | Isoprenaline | Quetiapine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1148,
24,
623
]
],
[
[
1148,
63,
827
],
[
827,
1,
623
]
],
[
[
1148,
64,
695
],
[
695,
1,
623
]
],
[
[
1148,
21,
29024
],
[
29024,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Isoprenaline may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Isoprenaline (C... |
DB11760 | DB14444 | 119 | 151 | [
"DDInter1742",
"DDInter924"
] | Talazoparib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
119,
24,
151
]
],
[
[
119,
63,
66
],
[
66,
24,
151
]
],
[
[
119,
24,
1619
],
[
1619,
24,
151
]
],
[
[
119,
64,
375
],
[
375,
24,... | [
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could... | Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Talazoparib may cause a moderate int... |
DB00682 | DB11837 | 126 | 1,297 | [
"DDInter1951",
"DDInter1351"
] | Warfarin | Osilodrostat | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
126,
24,
1297
]
],
[
[
126,
25,
112
],
[
112,
23,
1297
]
],
[
[
126,
24,
222
],
[
222,
23,
1297
]
],
[
[
126,
23,
271
],
[
271,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Warfarin may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may ca... |
DB00278 | DB01191 | 291 | 1,039 | [
"DDInter117",
"DDInter518"
] | Argatroban | Dexfenfluramine | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
291,
24,
1039
]
],
[
[
291,
25,
1046
],
[
1046,
63,
1039
]
],
[
[
291,
24,
578
],
[
578,
63,
1039
]
],
[
[
291,
24,
935
],
[
935,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Cap... | Argatroban may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor m... |
DB01041 | DB01452 | 770 | 993 | [
"DDInter1789",
"DDInter532"
] | Thalidomide | Diamorphine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
770,
24,
993
]
],
[
[
770,
63,
421
],
[
421,
40,
993
]
],
[
[
770,
63,
475
],
[
475,
25,
993
]
],
[
[
770,
63,
13
],
[
13,
24,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening i... |
DB00581 | DB08881 | 355 | 868 | [
"DDInter1018",
"DDInter1925"
] | Lactulose | Vemurafenib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
355,
24,
868
]
],
[
[
355,
21,
28658
],
[
28658,
60,
868
]
],
[
[
355,
23,
286
],
[
286,
63,
868
]
],
[
[
355,
24,
720
],
[
720,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused ... | Lactulose (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Vemurafenib (Compound)
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken... |
DB00031 | DB01138 | 20 | 804 | [
"DDInter1764",
"DDInter1726"
] | Tenecteplase | Sulfinpyrazone | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
20,
24,
804
]
],
[
[
20,
24,
998
],
[
998,
1,
804
]
],
[
[
20,
24,
1274
],
[
1274,
24,
804
]
],
[
[
20,
24,
1496
],
[
1496,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate in... |
DB00214 | DB09143 | 1,028 | 313 | [
"DDInter1836",
"DDInter1701"
] | Torasemide | Sonidegib | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
1028,
24,
313
]
],
[
[
1028,
63,
837
],
[
837,
23,
313
]
],
[
[
1028,
24,
101
],
[
101,
23,
313
]
],
[
[
1028,
24,
1478
],
[
1478,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and ... |
DB00372 | DB00790 | 999 | 664 | [
"DDInter1793",
"DDInter1431"
] | Thiethylperazine | Perindopril | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Moderate | 1 | [
[
[
999,
24,
664
]
],
[
[
999,
24,
1638
],
[
1638,
1,
664
]
],
[
[
999,
24,
954
],
[
954,
40,
664
]
],
[
[
999,
23,
460
],
[
460,
62... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindo... |
DB00673 | DB00783 | 723 | 1,438 | [
"DDInter112",
"DDInter679"
] | Aprepitant | Estradiol | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Moderate | 1 | [
[
[
723,
24,
1438
]
],
[
[
723,
63,
1561
],
[
1561,
40,
1438
]
],
[
[
723,
24,
35
],
[
35,
40,
1438
]
],
[
[
723,
6,
8374
],
[
8374,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Estradiol (Compound... |
DB01182 | DB08865 | 371 | 1,593 | [
"DDInter1534",
"DDInter448"
] | Propafenone | Crizotinib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
371,
25,
1593
]
],
[
[
371,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
371,
18,
4884
],
[
4884,
57,
1593
]
],
[
[
371,
21,
28771
],
[
28771,... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizo... | Propafenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Propafenone (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Crizotinib (Compound)
Propafenone (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by... |
DB00759 | DB11248 | 1,620 | 1,193 | [
"DDInter1783",
"DDInter1965"
] | Tetracycline | Zinc gluconate | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Moderate | 1 | [
[
[
1620,
24,
1193
]
],
[
[
1620,
24,
1096
],
[
1096,
23,
1193
]
],
[
[
1620,
24,
260
],
[
260,
62,
1193
]
],
[
[
1620,
63,
955
],
[
955,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with F... |
DB11988 | DB15233 | 270 | 1,650 | [
"DDInter1321",
"DDInter142"
] | Ocrelizumab | Avapritinib | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
270,
24,
1650
]
],
[
[
270,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
270,
24,
1476
],
[
1476,
24,
1650
]
],
[
[
270,
64,
908
],
[
908,
... | [
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[... | Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Bri... |
DB00026 | DB01285 | 1,184 | 708 | [
"DDInter94",
"DDInter445"
] | Anakinra | Corticotropin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1184,
24,
708
]
],
[
[
1184,
24,
126
],
[
126,
24,
708
]
],
[
[
1184,
24,
1136
],
[
1136,
63,
708
]
],
[
[
1184,
64,
1057
],
[
1057,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab ma... |
DB00860 | DB06717 | 891 | 875 | [
"DDInter1513",
"DDInter778"
] | Prednisolone | Fosaprepitant | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
891,
24,
875
]
],
[
[
891,
63,
723
],
[
723,
1,
875
]
],
[
[
891,
21,
29180
],
[
29180,
60,
875
]
],
[
[
891,
63,
1101
],
[
1101,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Prednisolone (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Prednisolone... |
DB00307 | DB14575 | 1,101 | 733 | [
"DDInter202",
"DDInter674"
] | Bexarotene | Eslicarbazepine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Minor | 0 | [
[
[
1101,
23,
733
]
],
[
[
1101,
62,
168
],
[
168,
23,
733
]
],
[
[
1101,
24,
1491
],
[
1491,
24,
733
]
],
[
[
1101,
25,
676
],
[
676,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mido... |
DB00771 | DB01148 | 262 | 1,128 | [
"DDInter397",
"DDInter738"
] | Clidinium | Flavoxate | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
262,
24,
1128
]
],
[
[
262,
40,
11264
],
[
11264,
40,
1128
]
],
[
[
262,
6,
7992
],
[
7992,
45,
1128
]
],
[
[
262,
24,
537
],
[
537,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles {... | Clidinium (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Flavoxate (Compound)
Clidinium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Flavoxate (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may ca... |
DB08816 | DB11978 | 578 | 124 | [
"DDInter1802",
"DDInter822"
] | Ticagrelor | Glasdegib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
578,
24,
124
]
],
[
[
578,
23,
1135
],
[
1135,
23,
124
]
],
[
[
578,
63,
475
],
[
475,
24,
124
]
],
[
[
578,
24,
180
],
[
180,
6... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may ca... |
DB00106 | DB00927 | 618 | 1,559 | [
"DDInter4",
"DDInter712"
] | Abarelix | Famotidine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
618,
24,
1559
]
],
[
[
618,
23,
1247
],
[
1247,
62,
1559
]
],
[
[
618,
24,
286
],
[
286,
62,
1559
]
],
[
[
618,
23,
112
],
[
112,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Famotidine
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxi... |
DB00675 | DB14881 | 888 | 180 | [
"DDInter1744",
"DDInter1329"
] | Tamoxifen | Oliceridine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
888,
24,
180
]
],
[
[
888,
23,
112
],
[
112,
23,
180
]
],
[
[
888,
24,
401
],
[
401,
24,
180
]
],
[
[
888,
63,
618
],
[
618,
24,... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB01309 | DB06016 | 1,254 | 1,508 | [
"DDInter933",
"DDInter300"
] | Insulin glulisine | Cariprazine | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1254,
24,
1508
]
],
[
[
1254,
24,
1450
],
[
1450,
63,
1508
]
],
[
[
1254,
63,
245
],
[
245,
24,
1508
]
],
[
[
1254,
62,
274
],
[
274,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozi... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00317 | DB08931 | 883 | 947 | [
"DDInter810",
"DDInter1600"
] | Gefitinib | Riociguat | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
883,
24,
947
]
],
[
[
883,
24,
379
],
[
379,
24,
947
]
],
[
[
883,
24,
913
],
[
913,
63,
947
]
],
[
[
883,
63,
1324
],
[
1324,
2... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalut... |
DB00757 | DB01591 | 1,166 | 667 | [
"DDInter581",
"DDInter1696"
] | Dolasetron | Solifenacin | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Major | 2 | [
[
[
1166,
25,
667
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
667
]
],
[
[
1166,
21,
28703
],
[
28703,
60,
667
]
],
[
[
1166,
23,
112
],
[
112,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Solife... | Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Dolasetron (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Solifenacin (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB00352 | DB04868 | 482 | 478 | [
"DDInter1814",
"DDInter1293"
] | Tioguanine | Nilotinib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
482,
24,
478
]
],
[
[
482,
24,
1468
],
[
1468,
63,
478
]
],
[
[
482,
5,
11555
],
[
11555,
44,
478
]
],
[
[
482,
21,
29544
],
[
29544,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Tioguanine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib ... |
DB00501 | DB00518 | 752 | 510 | [
"DDInter380",
"DDInter35"
] | Cimetidine | Albendazole | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Minor | 0 | [
[
[
752,
23,
510
]
],
[
[
752,
23,
1370
],
[
1370,
40,
510
]
],
[
[
752,
6,
4973
],
[
4973,
45,
510
]
],
[
[
752,
18,
8954
],
[
8954,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albendazole"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mebendazole"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Mebendazole and Mebendazole (Compound) resembles Albendazole (Compound)
Cimetidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Albendazole (Compound)
Cimetidine (Compound) downregulates HACD3 (Gene) and HACD3 (Gene) ... |
DB00197 | DB00673 | 1,324 | 723 | [
"DDInter1881",
"DDInter112"
] | Troglitazone | Aprepitant | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1324,
24,
723
]
],
[
[
1324,
24,
875
],
[
875,
40,
723
]
],
[
[
1324,
24,
1627
],
[
1627,
62,
723
]
],
[
[
1324,
23,
271
],
[
271,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction t... |
DB00635 | DB13139 | 1,573 | 1,032 | [
"DDInter1515",
"DDInter1063"
] | Prednisone | Levosalbutamol | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Minor | 0 | [
[
[
1573,
23,
1032
]
],
[
[
1573,
1,
1486
],
[
1486,
23,
1032
]
],
[
[
1573,
40,
251
],
[
251,
23,
1032
]
],
[
[
1573,
24,
1213
],
[
1213,... | [
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} m... | Prednisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a minor interaction that can limit clinical effects when ... |
DB00059 | DB08880 | 1,560 | 1,510 | [
"DDInter1404",
"DDInter1771"
] | Pegaspargase | Teriflunomide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1560,
25,
1510
]
],
[
[
1560,
24,
221
],
[
221,
63,
1510
]
],
[
[
1560,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
1560,
24,
208
],
[
208,
... | [
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formalde... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Pegaspargase may cause ... |
DB00047 | DB00841 | 176 | 532 | [
"DDInter932",
"DDInter577"
] | Insulin glargine | Dobutamine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Moderate | 1 | [
[
[
176,
24,
532
]
],
[
[
176,
24,
817
],
[
817,
40,
532
]
],
[
[
176,
24,
1052
],
[
1052,
1,
532
]
],
[
[
176,
24,
123
],
[
123,
63... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Dobutamine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine (Compound) resembles Dobutamine (Comp... |
DB00196 | DB04946 | 600 | 924 | [
"DDInter743",
"DDInter907"
] | Fluconazole | Iloperidone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
600,
25,
924
]
],
[
[
600,
24,
883
],
[
883,
1,
924
]
],
[
[
600,
25,
1425
],
[
1425,
25,
924
]
],
[
[
600,
24,
519
],
[
519,
40... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitini... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Iloperidone (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken... |
DB11348 | DB13997 | 1,065 | 133 | [
"DDInter279",
"DDInter163"
] | Calcium Phosphate | Baloxavir marboxil | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label]. | Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.[A39895, A251755] It is a prodrug of [baloxavir] with an improved absorption profile than its active metabolite due to the add... | Moderate | 1 | [
[
[
1065,
24,
133
]
],
[
[
1065,
63,
1008
],
[
1008,
24,
428
],
[
428,
63,
133
]
],
[
[
1065,
63,
1008
],
[
1008,
63,
417
],
[
417,
24,
... | [
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baloxavir marboxil"
]
],
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rised... | Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when... |
DB00208 | DB00407 | 1,018 | 202 | [
"DDInter1804",
"DDInter115"
] | Ticlopidine | Ardeparin | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Major | 2 | [
[
[
1018,
25,
202
]
],
[
[
1018,
21,
29215
],
[
29215,
60,
202
]
],
[
[
1018,
63,
1560
],
[
1560,
24,
202
]
],
[
[
1018,
24,
738
],
[
738,... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
]
],
[
[
"Ticlopidine",
"{u} (Compound) causes {v} (Side Effect)",
"Ecchymosis"
],
[
"Ecchymosis",
"{u} (Side Effect) is caused by {v} (C... | Ticlopidine (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Ardeparin (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00348 | DB11652 | 254 | 1,155 | [
"DDInter1300",
"DDInter1891"
] | Nitisinone | Tucatinib | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
254,
24,
1155
]
],
[
[
254,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
254,
24,
609
],
[
609,
24,
1155
]
],
[
[
254,
24,
1320
],
[
1320,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clari... |
DB00227 | DB01259 | 1,463 | 392 | [
"DDInter1098",
"DDInter1024"
] | Lovastatin | Lapatinib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1463,
24,
392
]
],
[
[
1463,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1463,
7,
10248
],
[
10248,
46,
392
]
],
[
[
1463,
18,
15501
],
[
1550... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Lovastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Lovastatin (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Lapatinib (Compound)
Lovastatin (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Lapatinib (Compound)
Lovastatin (Com... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.